Methyl eugenol

Research use only, not for human use.

Methyleugenol (ME) is a natural constituent of the essential oils of a number of plants widely used in foodstuffs as flavouring agents.

Methyleugenol (ME) is a natural constituent of the essential oils of a number of plants widely used in foodstuffs as flavouring agents, in view of the carcinogenic potential of ME, the need to check its presence in food products with effective analytical methods. Methyleugenol has insecticidal properties. Methyleugenol can inhibit the production of nitric oxide and decreased the protein expression of inducible nitric oxide synthase, it down-regulates the production of pro-inflammatory cytokines in the ischemic brain as well as in immunostimulated mixed glial cells; indicates that methyleugenol could be useful for the treatment of ischemia/inflammation-related diseases. Methyleugenol has cytotoxicity and genotoxicity. Intravenous (i.v.) treatment with methyleugenol (ME) in either anesthetized or conscious rats elicits hypotension, an effect that seems related to an active vascular relaxation rather than withdrawal of sympathetic tone. Methyleugenol has antinociceptive effect on the second phase of formalin-induced pain, may be due to the inhibition of N-methyl-d-aspartic acid (NMDA) receptor-mediated hyperalgesia via GABA(A) receptors. Methyleugenol has elaxant and antispasmodic actions on guinea-pig isolated ileum.

Cell Autophagy Assay Cell Line:RB355 (Human retinoblastoma cells)Concentration:50 μM Incubation Time:24 h Result:Significantly increased the expression of LC3-II in a dose-dependent manner and decreased the expression of p62.Weakened the inhibitory effect of the autophagy inhibitor gastrostatin.Western Blot Analysis Cell Line:RB355 (Human retinoblastoma cells) Concentration:50 μM Incubation Time:48 h Result:Inhibited the PI3K/mTOR/Akt signaling pathway.Down-regulated the expression of m-TOR and pm-TOR proteins in a concentration-dependent manner.Down-regulated the expression of PI3K/Akt protein.

Animal Model:Adult Wistar rats (Rattus norvegicus) model of intestinal ischemia/reperfusion injury Dosage:100 mg/kg Administration:Oral intubation; Once daily for 30 days. Before underwent laparotomy with SMA occlusion 30 min of ischemia followed by 60 min of reperfusion.Result:Significantly decreased the elevated LDH, MDA, and NO levels and concurrently increased the antioxidant biomarkers under test in the intestinal tissue.Significantly downregulate the mRNA expression levels of TNF-α and IL-6.

Methyleugenol | Methyl eugenol | Eugenol methyl ether

Wnt/Notch/Hedgehog

Wnt/beta/catenin

GABAA

Others-Field

——

93-15-2

178.23

C11H14O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (561.07 mM)

COC1=C(C=C(C=C1)CC=C)OC

1,2-Dimethoxy-4-prop-2-enylbenzene

(-20℃)

With Ice Pack

≥ 2 years